


**Charts (500)
Models (14)**

Customised Charts

Size 20"x30" Laminated & Mounted Framed on Board




Models




PCM 01
ANTIMICROBIAL DRUG ACTION ON
DIFFERENT SITES OF BACTERIAL CELL



PCM 02
TYROSINE KINASE
RECEPTOR



PCM 03
NEUROHUMORAL TRANSMISSION
OF ACETYLCHOLINE



PCM 04
GABA_A RECEPTOR



PCM 05
ANTIBACTERIAL DRUGS ACTION
AT RIBOSOMES

- PCM 01 ANTIMICROBIAL DRUG ACTION ON DIFFERENT SITES OF BACTERIAL CELL
- PCM 02 TYROSINE KINASE RECEPTOR
- PCM 03 NEUROHUMORAL TRANSMISSION OF ACETYLCHOLINE
- PCM 04 GABA_A RECEPTOR
- PCM 05 ANTIBACTERIAL DRUGS ACTION AT RIBOSOMES
- PCM 06 ADVERSE EFFECTS OF CORTICOSTEROIDS
- PCM 07 SITE OF DRUG ACTION IN GLAUCOMA
- PCM 08 DRUG SIDE EFFECTS
- PCM 09 PAIN PATHWAYS
- PCM 10 HYPERTENSION
- PCM 11 DIABETES MELLITUS (Sulfonylureas, Biguanides)
- PCM 12 ANTIDIARRHEAL DRUGS & THEIR ADVERSE EFFECTS
- PCM 13 CORTI COSTERIODS ACTION IN BRONCHIAL ASTHMA & ADVERSE EFFECTS
- PCM 14 HIV INFECTIONS, NRTIS & NON-NRTIS

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips
Thick Laminated & Framed on NU-Wood Board

DPHc 02 Pharmacology of Central Nervous System (in 7 Charts)

- A. Neurohumoral transmission in the C.N.S.
- B. General Anesthetics.
- C. Anti-epileptics drugs.
- D. Anti-Parkinsonian Drugs.
- E. Analgesics, Antipyretics and Anti-gout drugs.
- F. Narcotic analgesics and antagonists.
- G. C.N.S. Stimulants

DPHc 05 Drugs acting on urinary system (in 2 Charts)

- A. Fluid and electrolyte balance
- B. Diuretics

DPHc 06 Autocoids (in 2 Charts)

- A. Histamine, 5- HT and their antagonists.
- B. Prostaglandins, thromboxanes and leukotrienes.

DPHc 09 Pharmacology of Endocrine System (in 6 Charts)

- A. Hypothalamic and pituitary hormones.
- B. Thyroid hormones and anti thyroid drugs.
- C. Insulin, oral hypoglycaemic agents and Glucagon.
- D. ACTH and corticosteroids
- E. Androgens and anabolic steroids
- F. Estrogens, progesterone and oral contraceptives


DPHc 03 Pharmacology of Cardiovascular System (in 5 Charts)

- A. Digitalis and cardiac glycosides.
- B. Antihypertensive drugs.
- C. Antianginal and Vasodilator drugs.
- D. Antiarrhythmic drugs
- E. Antihyperlipedimic drugs

DPHc 04 Drugs Acting on the Hemopoietic System (in 2 Charts)

- A. Anticoagulants, Vitamin K and hemostatic agents.
- B. Fibrinolytic and anti-platelet drugs.

- DPHc 21 Events during biofilm formation
- DPHc 22 Identification and classification process of bacteria by culturing
- DPHc 23 Schematic representation of immune defenses in the oral cavity.
- DPHc 24 Schematic illustration of microbial complexes detected in dental plaque
- DPHc 25 DNA Viruses
- DPHc 26 RNA viruses
- DPHc 27 Clinical appearance of viral infections in the oral cavity
- DPHc 28 How oral microbes produce local inflammation to influence systemic pathology.
- DPHc 29 Structure of viruses
- DPHc 30 Morphology of Bacteria
- DPHc 31 Schematic Diagram of an Immunoglobulin (IgG)
- DPHc 32 Oral Candidiasis
- DPHc 33 Hypersensitivity Reactions
- DPHc 34 Malaria parasites
- DPHc 35 HIV life cycle
- DPHc 36 Bacterial cell wall
- DPHc 37 Action of Sympathetic and Parasympathetic Nervous Systems on Effector Organs
- DPHc 38 Therapeutic Indications for the Primary Anticonvulsant Agents
- DPHc 39 Action Potential of a Purkinje Fiber
- DPHc 40 Schematic Diagram of the Effects of Antiarrhythmic Drugs
- DPHc 41 Metabolism of Plasma Lipoproteins
- DPHc 42 Ventricular Function Curves in the Normal Heart, in Heart Failure (hf), and in Hf Treated with Digitalis
- DPHc 43 Antiretroviral Drugs
- DPHc 44 Types of Action of Drugs used to Treat peptic Ulcer Disease
- DPHc 45 Mechanism of Action of Cyclosporine and Tacrolimus.
- DPHc 46 Biosynthesis of Thyroid Hormones.
- DPHc 47 Sites of Action of Diuretic Drugs in the Nephron
- DPHc 48 Drug Administration from application to distribution in the body
- DPHc 49 Drug administration dosage forms for parental, pulmonary, rectal or vaginal and cutaneous application
- DPHc 50 Drug administration dosage forms for oral, ocular and nasal applications



DPHc 39 Action Potential of a Purkinje Fiber

PHARMACOLOGY CHARTS


Pharmacology (Dbios)

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

- DPhc 51 Pharmacokinetics (3 charts)**
(A) Routes of Drug administration
(B) Absorption of Drugs, bioavailability & Drug distribution
(C) Binding of Drugs to plasma proteins and Drug metabolism & Drug elimination
- DPhc 52 Drug – Receptor interactions and pharmacodynamics**
- DPhc 53 The Automatic nervous system (2 charts)**
(A) Introduction, efferent neurons, action of sympathetic and parasympathetic nervous system on effector organs
(B) Functions of parasympathetic nervous system, chemical signaling between cells and second messenger systems in intracellular response
- DPhc 54 Cholinergic Agonists (2 charts)**
(A) Overview, the cholinergic neuron
(B) Cholinergic receptors, direct acting cholinergic agonists, anticholinesterases (Reversible and irreversible)
- DPhc 55 Cholinergic Antagonists (2 charts)**
(A) Cholinergic antagonists, site of actions of cholinergic antagonists
(B) Onset and duration of action of Neuromuscular blocking agents, mechanism of action of depolarizing neuromuscular blocking drugs
- DPhc 56 Adrenergic agonists (3 charts)**
(A) Overview, site of action of adrenergic agonists, synthesis and release of norepinephrine from the adrenergic neuron
(B) Types of adrenergic receptors, major effects by α and β adrenoceptors, structures of important adrenergic agonists.
(C) Cardiovascular effects of IV. Of low doses of epinephrine norepinephrine isoproterenol, effects of inhaled adrenergic agonists
- DPhc 57 Adrenergic Antagonists (2 charts)**
(A) Adrenergic blockers, covalent inactivation of α adrenoceptor by phenoxy benzamine, actions of propranolol and other β -blockers
(B) Comparison of agonists antagonists and partial agonists of β -adrenoceptors, some clinical applications of β -blockers, summary of β -adrenergic antagonists
- DPhc 58 Treatment of Neurodegenerative Diseases (2 charts)**
(A) Summary of antiparkinson & anti-alzheimer drugs, summary of some neurotransmitters of CNS Synaptic potentials (Excitatory and inhibitory pathways)
(B) Overview of Parkinson disease, Drugs used in Parkinson disease effects of entacapone on dopa concentration in the CNS.
- Dphc 59 Anxiolytic and hypnotic drugs**
(A) Summary of anxiolytic and hypnotic drugs, benzodiazepine GABA chloride ion channel complex therapeutic disadvantages and advantages of anxiolytic and hypnotic agents
- DPhc 60 Central Nervous system Stimulants**
(A) CNS stimulants mechanism of action of cocaine amphetamine and cannabinoid receptor
- DPhc 61 Anesthetics**
Summary of anesthetics, components of balanced anesthesia, modulation of a ligand-gated membrane channel and therapeutic disadvantages and advantages of some anesthetic agents.
- DPhc 62 Antidepressant Drugs**
Summary of antidepressants, mechanism of action of SSRI and TCA drugs mechanism of action of monoamine oxidase inhibitors
- DPhc 63 Neuroleptic Drugs**
Summary of neuroleptic drugs, dopamine blocking actions of neuroleptic drugs, mechanism of action of neuroleptic drugs
- DPhc 64 Opioid Analgesics and Antagonists**
Summary of opioid analgesics, mechanism of action of μ -opioid receptor agonists competition of naloxone with opioid agonists
- DPhc 66 Treatment of Heart Failure (3 charts)**
(A) Summary of Drugs used to treat Heart Failure Physiology of Muscle Contraction action potential of a Purkinje fiber.
(B) Ion movements during the contraction of cardiac muscle cardiovascular consequences of heart failure, effects of angiotensin converting enzyme inhibitors.
(C) Mechanism of action of cardiac glycosides ventricular function curves in the normal heart in heart failure, and in HF treated with digitalis, sites of action by β -adrenergic agonists on heart muscle.
- DPhc 67 Antiarrhythmic Drugs (3 charts)**
(A) Summary of antiarrhythmic drugs Therapeutic indications for some commonly encountered arrhythmias, Schematic representation of reentry.
(B) Action of antiarrhythmic drugs, schematic diagram for the effects of class IA, IB, IC agents
(C) Schematic diagram of the effects of class III & class IV agents



Dphc 52

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

DPhc 68 Antianginal Drugs

Summary of antianginal drugs, effects of intrates and nitrites on smooth muscle, blood flow in a coronary artery partially blocked with atherosclerotic plaques, treatment of angina in patients with concomitant diseases

Dphc 69 Antihypertensive Drugs (2 charts)

- (A) Summary of antihypertensive drugs, major factors influencing blood pressure, response of the autonomic nervous system and the renin-angiotensin system.
- (B) Treatment of hypertension in patients with concomitant diseases, actions of thiazide diuretics, action of b-adrenoceptor blocking agents, effects of ACE inhibitors, action of calcium - channel blockers, therapeutic applications of calcium channel blockers

DPhc 70 Drugs Affecting the Blood (3 charts)

- (A) Summary of drugs used in treating dysfunctions of the blood, formation of a hemostatic plug
- (B) Activation and aggregation of platelets, role of aspirin, mechanism of action of ticlopidine and clopidogrel, formation of a fibrin clot, mechanism of action of heparin
- (C) Mechanism of action of warfarin, drugs affecting the anticoagulant effects of warfarin, mechanism of action of streptokinase, causes and consequences

DPhc 71 Antihyperlipidemic Drugs (2 charts)

- (A) Summary of antihyperlipidemic drugs, metabolism of plasma lipoproteins and related genetic diseases
- (B) Inhibition of HMG-CoA reductase by the statin drugs, inhibition of lipolysis in adipose tissue by niacin, activation of lipoprotein lipase by gemfibrozil, bile acid-binding resins

DPhc 72 Diuretic Drugs

Summary of diuretic drugs, sites of action of the diuretic drugs, sites of transport of solutes and water along the nephron, role of carbonic anhydrase in sodium retention by epithelial cells of renal tubule

DPhc 73 Hormones of the Pituitary and Thyroid (2 charts)

- (A) Some hormones and drugs affecting the hypothalamus, pituitary and thyroid, Hypothalamic and anterior pituitary hormones, secretions and actions of adreno-corticotrophic hormone
- (B) Secretions of FSH and LH, actions of oxytocin and vasopression, biosynthesis of thyroid hormones

DPhc 74 Insulin and oral Hypoglycemic Drug (3 charts)

- (A) Summary of hypoglycemic agents, comparison of Type 1 and Type 2 diabetes, major factors contributing to hyperglycemia, Duration of type 2 diabetes.
- (B) Onset and duration of action of human insulin and insulin analogs, duration of action of some oral hypoglycemic agents, drugs interacting with sulfonyl-urea drugs.
- (C) Summary of oral hypoglycemic agents

DPhc 75 Estrogens and Androgens

Summary of sex hormones, benefits associated with postmenopausal estrogen replacement, regulation of secretion of testosterone, administration and fate of androgens

Dphc 76 Adrenocorticosteroid Hormones

Summary of adrenal corticosteroids, regulation of corticosteroid secretion, gene regulation by glucocorticoids, pharmacologic effects

Dphc 77 Drugs affecting the Respiratory system (2 charts)

- (A) Summary of drugs affecting the respiratory system, Comparison of bronchi of normal and asthmatic individuals. Treatment of asthma. Pharmacokinetics of inhaled glucocorticoids, Effect of spacer on the delivery of inhaled aerosol.
- (B) Sites of action of leukotriene-modifying drugs, Treatment of stable chronic obstructive pulmonary disease (COPD). FEV₁ = forced expiratory volume in one second.

DPhc 78 Gastrointestinal and Antiemetic Drugs. (2 charts)


- (A) Summary of drugs used to treat peptic ulcer disease, Helicobacter pylori in association with gastric mucosa effects of acetylcholine, histamine, prostaglandin E₂, and gastrin on gastrin acid secretion, administration and fate of cimetidine, drug interactions with cimetidine.
- (B) Comparison of emetic potential of anticancer drugs, summary of drugs used to treat chemotherapy-induced nausea and vomiting, potencies of antiemetic drugs, summary of drugs used to treat diarrhea and constipation.

DPhc 79 Erectile dysfunction, osteoporosis and obesity

Summary of drugs used in the treatment of erectile dysfunction, osteoporosis and obesity, mechanism of penile erection, effect of phosphodiesterase inhibitors on cyclic guanosine monophosphate (cGMP) changes in bone morphology seen in osteoporosis

DPhc 80 Principles of Antimicrobial therapy (2 charts)

- (A) Some laboratory techniques that are useful in diagnosis of microbial diseases Determination of minimum inhibitory concentration and minimum bactericidal concentration of an antibiotic, essential features of blood-brain barrier, schematic representation of blood-brain barrier.
- (B) Bar chart showing the six most commonly used drug families, color-coded representation of medically important microorganisms Mechanisms of resistance to antibiotics, sites of antimicrobial actions



Dphc 71B



Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

Dphc 81 Inhibitors of cell wall synthesis (4 charts)

- (A) Summary of antimicrobial agents affecting cell wall synthesis, Structural features of β -lactam antibiotics, bacterial cell wall of gram-positive bacteria.
- (B) Typical Therapeutic Applications of penicillin G ampicillin, Stability of the penicillins to acid, administration & fate of penicillin.
- (C) Summary of Therapeutic applications of cephalosporins, Administration and fate, Characteristics of some clinically useful cephalosporins.
- (D) Structural features of imipenem and Aztreonam antimicrobial spectrum of imipenem, vancomycin Administration & fate of vancomycin.

DPhc 82 Protein Synthesis Inhibitors (4 charts)

- (A) Summary of protein synthesis inhibitors, Typical therapeutic applications of tetracyclines, Administration and fate of tetracycline, M.O.A of tetracycline
- (B) Mechanism of action of amino glycosides, typical therapeutic applications of aminoglycosides, Administration and fate of aminoglycosides.
- (C) Macrolides: M.O.A of erythromycin and clindamycin. Typical therapeutic applications of macrolides. Administration and fate of macrolide Adverse effects of macrolide.
- (D) Inhibition of the cytochrome P450 system by erythromycin, Administration and fate of chloramphenicol, inhibition of the cytochrome P450 system by Chloramphenicol, Admin & fate of clindamycin, MOA of linezolid, Antimicrobial spectrum of linezolid.

DPhc 83 Quinolones, Folic Acid antagonists and urinary tract Antiseptics. (3 charts)

- (A) Summary of quinolones, Action of type II DNA topoisomerase, Summary of antimicrobial spectrum of quinolones, Typical therapeutic applications of ciprofloxacin Administration & fate of fluoroquinolones.
- (B) Inhibition of tetrahydrofolate synthesis by sulfonamides and trimethoprim, admin and fate of sulfonamides, typical therapeutic applications of co-trimoxazole, admin and fate of co-trimoxazole, formation of formaldehyde.
- (C) Inhibition of tetrahydrofolate synthesis by sulfonamides and trimethoprim, Admin and fate of sulfonamides, Typical therapeutic applications of co-trimoxazole, Admin and fate of co-trimoxazole, Formation of formaldehyde.

DPhc 84 Antimycobacterial Drugs

Summary of drugs, Administration & fate of Isoniazid, Rifampin, Therapeutic margins for antitubercular drugs.

DPhc 85 Antifungal Drugs

Antifungal drugs, Prugs for subcutaneous and systemic mycotic infections

DPhc 86 Antiprotozoal Drugs

Summary of antiprotozoal agents, Fate of metronidazole, diloxanide, primaquine Action of chloroquine, fate of chloroquine melarsoprol pentamidine, stibogluconate.

Dphc 87 Anthelmintic Drugs (2 charts)

- (A) Summary of nematode infections & therapy
- (B) Characteristics of and therapy for commonly encountered trematode infections, cestode infections.

Dphc 88 Antiviral Drugs (5 charts)

- (A) Antiviral drugs, Fate of oseltamivir, zanamivir. Amantadine rimantadine ribavirin.
- (B) Action of acyclovir, fate of Acyclovir, Cidofovir, Foscarnet.
- (C) Administration and fate of ganciclovir penciclovir and famciclovir antiviral agents.
- (D) Drugs used to prevent HIV from replicating HAART.
- (E) Admin and fate of zidovudine, didanosine, zalcitabine and stavudine, tenofovir, nevirapine, delavirdine

DPhc 89 Anticancer Drugs (7 charts)

- (A) Summary, effects of various treatments
- (B) Effects of chemotherapeutic agents on mammalian cells, mechanism of action of methotrexate.
- (C) Action of 6-mercaptopurine, fate of 6-mercaptopurine action of 5-FU. Fluorouracil, capecitabine.
- (D) Administration and fate of cytarabine, action of gemcitabine, fate of dactinomycin Doxorubicin.
- (E) Alkylation of guanine fate of cyclophosphamide lomustine temozolomide.
- (F) Action of microtubule inhibitors, steroid hormones,
- (G) Fate of cisplatin action of DNA Topoisomerases Etoposide.

Dphc 90 Immunosuppressive Drugs (2 charts)


- (A) Immunosuppressant drugs, selected cytokines M.D.A. cyclosporine and tacrolimus.
- (B) Sites of action of common immunosuppressants

DPhc 91 Anti-inflammatory Drugs (3 charts)

- (A) Summary of anti-inflammatory drugs, COX-1 and COX-2, synthesis of prostaglandins and leukotrienes.
- (B) Metabolism of aspirin, action of NSAIDs, Renal effect of aspirin, effects of salicylate drugs Interacting with salicylates.
- (C) Metabolism of acetaminophen, Site of leflunomide Role of uric acid in inflammation of gout.

DPhc 92 Autacoids and Antagonists (2 charts)

- (A) Summary of drugs affecting autacoids Biosynthesis and action of histamine, Effects of H1 antihistamines.
- (B) Drugs for the treatment and prophylaxis of migraine



Dphc 86

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

Major Ways in Which Drugs Work

- Dphc 102 Eliminate External and Internal Threats
- Dphc 104 Replenish or Neutralize Endogenous Chemicals
- Dphc 105 Modulate Physiologic Processes

Chemical Communication

- Dphc 106 Chemical Transmission at the Synapse
- Dphc 107 Synapse Morphology

Pharmacodynamics

- Dphc 108 Receptors and Signaling
- Dphc 109 Receptor Subtypes
- Dphc 110 Agonists
- Dphc 111 Antagonists
- Dphc 112 Stereochemistry and 3-Dimensional Fit
- Dphc 113 Receptor-Effector Coupling
- Dphc 114 Signal Transduction and Cross Talk
- Dphc 115 Second-Messenger Pathways
- Dphc 116 Ligand-Gated Ion Channels
- Dphc 117 G Protein-Coupled Receptors
- Dphc 118 Trk Receptors
- Dphc 119 Nuclear Receptors
- Dphc 120 Up-regulation and Down-regulation of Receptors
- Dphc 121 Dose-Response Curves
- Dphc 122 Potency
- Dphc 122a Efficacy
- Dphc 123 Inverse Agonists
- Dphc 124 Antagonists: Surmountable (reversible) and Nonsurmountable (Irreversible)

Pharmacokinetics

- Dphc 125 Routes of Administration
- Dphc 126 First-Pass Effect
- Dphc 127 Membrane Transport
- Dphc 128 Distribution
- Dphc 129 Barriers
- Dphc 130 Metabolism (Biotransformation) of Drugs
- Dphc 131 Cytochrome P-450 (CYP 450) Enzymes
- Dphc 132 Metabolic Enzyme Induction and Inhibition
- Dphc 133 Elimination

Organization of the Nervous System

- Dphc 136 Organization of the Nervous System
- Dphc 137 Action of Drugs on Nerve Excitability

Somatic Nervous System

- Dphc 138 Interface of the Central and Peripheral Nervous Systems and Organization of the somatic Division.
- Dphc 139 Neuromuscular Transmission
- Dphc 140 Nicotinic Acetylcholine Receptor
- Dphc 141 Physiology of the Neuromuscular Junction
- Dphc 142. Pharmacology of the Neuromuscular Junction
- Dphc 143 Mechanism of Action of Acetylcholinesterase Inhibitors
- Dphc 144 Neuromuscular Blocking Agents: Nondepolarizing and Depolarizing

Autonomic Nervous System

- Dphc 145 Autonomic Nervous System: Schema
- Dphc 146 Sympathetic Fight or Flight Response
- Dphc 147 Cholinergic and Adrenergic Synapses
- Dphc 148 Example of Cholinergic and Adrenergic Drug Treatment: Glaucoma
- Dphc 149 Cholinergic Receptors
- Dphc 150 Cholinergic Drugs
- Dphc 152 Example of Cholinergic Drug Treatment: Myasthenia Gravis
- Dphc 153 Adrenergic Receptors
- Dphc 154 Adrenergic Drugs
- Dphc 155 Drugs That Act on the Autonomic Nervous System
- Dphc 156 Drug Side Effect

Introduction to the CNS and Drug Action

- Dphc 158 Development of the Nervous System
- Dphc 159 Anatomy of the Nervous System
- Dphc 160 Functional Correlations and Visualization of Brain Structures
- Dphc 161 Resting Membrane and Action Potentials
- Dphc 162 Excitatory and Inhibitory Postsynaptic Potentials
- Dphc 163 Central Nervous System Neurotransmitters, Receptors, and Drug Targets

Sedative-Hypnotic Drugs

- Dphc 164 GABA4 Receptor Complex and Sedative-Hypnotic Drugs

Anxiolytic Agents

- Dphc 165 Clinical Anxiety
- Dphc 166 Anxiolytic Agents

Antiepileptic Agent

- Dphc 167 Causes of Seizures and Their Treatment
- Dphc 168 Epilepsy: Generalized Seizures and Status Epilepticus
- Dphc 169 Epilepsy: Partial and Absence Seizures

Antidepressants

- Dphc 171 Clinical Depression
- Dphc 172 Antidepressant's mechanisms of Action

Drugs Affecting Bipolar Disorder and OCD

- Dphc 173 Bipolar Disorder and Compulsive Behavior

Antipsychotic Agents

- Dphc 174 Psychosis and Dopamine Pathways

Drugs Affecting Movement Disorders and Other Neurodegenerative Disorders

- Dphc 175 Motor Tracts, Basal Ganglia, and Dopamine Pathways
- Dphc 177 Parkinsonism: Symptoms and Defect
- Dphc 178 Parkinsonism: Levodopa, Carbidopa, and Other Drugs
- Dphc 179 Huntington Disease and Tourette syndrome
- Dphc 180 Alzheimer Disease: Symptoms, Course, and Pathology
- Dphc 181 Alzheimer Disease: Cholinergic Involvement and Drugs
- Dphc 183 Stroke: Symptoms and Drug Treatment

CNS Skeletal Muscle Relaxants

- Dphc 184 Motor Neurons and Drugs

Analgesics and Anesthetics

- Dphc 185 Pain Pathways
- Dphc 186 Local Anesthetics: Spinal Afferents and Local Anesthetic Mechanisms of Action
- Dphc 187 General Anesthetics: Properties
- Dphc 188 Opioids: Endogenous Opioid Pathway
- Dphc 189 Opioids: Receptor-Transduction Mechanisms
- Dphc 190 Nonopioids: NSAID's, Selective Cyclooxygenase-2 Inhibitors, and Acetaminophen
- Dphc 191 Sumatriptans and Reuptake Inhibitors

Drugs Used in Disorders of the Cardiovascular System

Cardiovascular System: Anatomy, Function, and Regulation of the Heart

- Dphc 194 Cardiovascular Function: Anatomy
- Dphc 195 Cardiovascular Function: Definition of Terms and Regulation
- Dphc 196 Role of Catecholamines in Heart Function
- Dphc 197 Sympathetic and Parasympathetic Regulation of Heart Function
- Dphc 198 Synthesis and Storage of Catecholamines
- Dphc 199 Regulation of Norepinephrine Release
- Dphc 200 Inactivation of Norepinephrine



Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

Hypercholesterolemia and Atherosclerosis

- Dphc 201 Hypercholesterolemia: Causes
- Dphc 202 Hypercholesterolemia: Pharmacologic Therapy

Angina

- Dphc 203 Angina Overview
- Dphc 204 Nitrates for Angina Treatment: Classes, Administration Routes, Pharmacology, and

Adverse Effects

- Dphc 205 Nitroglycerin in Angina Treatment
- Dphc 206 Nitroglycerin: Mechanism of Action
- Dphc 207 Calcium Channel Antagonists
- Dphc 208 Drug Summary of Angina

Heart Failure

- DPHC 209 Heart Failure Overview
- DPHC 210 Heart Failure Treatment
- DPHC 211 Heart Failure Treatment b-Adrenergic Stimulators and Blockers
- DPHC 212 Heart Failure Treatment Cardiac Glycosides

Arrhythmias

- DPHC 213 Cardiac Arrhythmias: General
- DPHC 215 Cardiac Arrhythmias: Treatment
- DPHC 217 Cardiac Arrhythmias: Drugs Classification

Hypertension

- Dphc 218 Hypertension Overview
- Dphc 219 Hypertension Causes
- Dphc 220 Hypertension Treatment: Diuretics
- Dphc 221 Hypertension Treatment: Angiotensin-Converting Enzyme Inhibitors
- Dphc 222 Hypertension Treatment: b and a Blockers
- Dphc 223 Hypertension Treatment: Minoxidil
- Dphc 224 Hypertension Treatment: Clonidine
- Dphc 225 Hypertension in Elderly Patients
- Dphc 226 Pheochromocytoma-Induced Hypertension
- Dphc 227 Hypertension in Cushing Syndrome

Peripheral Vascular Disease

- Dphc 228 Peripheral Vascular Disease

Drugs Used in Disorders of The Endocrine System

Hypothalamic and Pituitary Disorders

- Dphc 230 Regulation of Hypothalamic and Pituitary Hormones
- Dphc 232 Hypopituitarism
- Dphc 233 Growth Hormone Deficiency and Treatment
- Dphc 234 Growth Hormone Excess (Acromegaly) and Treatment

Thyroid Disorders

- Dphc 235 Thyroid Hormones
- Dphc 236 Thyroid Hormones: Synthesis, Release, and Regulation
- Dphc 237 Hypothyroidism
- Dphc 238 Hypothyroidism: Treatment of Choice
- Dphc 239 Liothyronine and T4/T3 Combinations
- Dphc 240 Hyperthyroidism
- Dphc 241 Hyperthyroidism: Treatment
- Dphc 242 Thioamides
- Dphc 243 Thioamides: Adverse Effects
- Dphc 244 Radioactive Iodine
- Dphc 245 Iodide
- Dphc 246 Adrenergic Antagonists

Corticosteroids and Adrenocortical Dysfunction

- Dphc 247 Regulation of Adrenal Hormones
- Dphc 248 Mineralocorticoids and Glucocorticoids

- Dphc 249 Corticosteroids
- Dphc 250 Cushing Syndrome
- Dphc 251 Ketoconazole
- Dphc 252 Metyrapone
- Dphc 253 Aminoglutethimide
- Dphc 254 Addison Disease, or Primary Adrenal Insufficiency

Diabetes Mellitus

- Dphc 255 The Pancreas and Insulin Production
- Dphc 256 Insulin Secretion
- Dphc 257 Lack of Insulin
- Dphc 258 Type 1 Diabetes Mellitus
- Dphc 259 Type 2 Diabetes Mellitus
- Dphc 260 Insulin Therapy
- Dphc 261 Reactions of Insulin: Hypoglycemia and Adipose Tissue Changes
- Dphc 262 Sulfonylureas
- Dphc 263 Biguanides
- Dphc 264 Meglitinides
- Dphc 265 a-glucosidase Inhibitors
- Dphc 266 Thiazolidinediones
- Dphc 267 Thiazolidinediones: Clinical Rationale and Adverse Effects

Drugs Used in Disorders of The Gastrointestinal System

Function and Regulation of the GI System

- Dphc 270 Enteric Nervous System
- Dphc 271 Integration of the Autonomic and Enteric Nervous Systems
- Dphc 272 Gastrointestinal Motility
- Dphc 274 Control of Peristalsis
- Dphc 275 Hormones of the Gastrointestinal Tract
- Dphc 276 Parietal Cell Function Regulation
- Dphc 277 Pancreatic Secretion
- Dphc 278 Defecation
- Dphc 279 Protein Digestion
- Dphc 280 Fat Digestion

Disorders of Colonic Motility

- Dphc 281 Colonic Motility and Treatment of Diarrhea
- Dphc 282 Antidiarrheal Drugs and Their Adverse Effects
- Dphc 283 Causes of Constipation
- Dphc 284 Treatment of Constipation

Functional Disorder of the Large Intestine

- Dphc 285 Treatment of Irritable Bowel Syndrome

Protozoal

- Dphc 287 Giardiasis

Peptic Ulcer

- Dphc 288 Helicobacter pylori infection Overview
- Dphc 289 Treatment of Helicobacter pylori Infection
- Dphc 290 Peptic Ulcer Treatment

Gastroesophageal Reflux Disease

- Dphc 291 Gastroesophageal Reflux Disease Overview
- Dphc 292 Gastroesophageal Reflux Disease Treatment

Pancreatitis

- Dphc 293 Pathologic Features of Gallstones

Cholelithiasis

- Dphc 295 Pathologic Features of Gallstones
- Dphc 296 Gallstone Pathogenesis and Treatment

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

Liver Pathogenesis and Pathology

- Dphc 297 Liver Function
- Dphc 298 Bilirubin Production and Excretion
- Dphc 299 Cirrhosis
- Dphc 300 Ascites

Nausea and Vomiting

- Dphc 302 Physiology of Emesis
- Dphc 304 Antiemetics

Drugs used in Disorders of the Respiratory system

Respiration: Introduction to Physiology and Pathology

- Dphc 306 Respiration Overview
- Dphc 307 Respiratory Diseases

Allergy

- Dphc 308 Allergy
- Dphc 309 Leukocyte Function
- Dphc 310 Allergic Rhinitis

Asthma

- Dphc 311 Introduction to Asthma
- Dphc 312 Extrinsic and Intrinsic Asthma
- Dphc 314 Asthma Pharmacotherapy
- Dphc 315 Anti-IgE Antibodies
- Dphc 316 Mast cell Degranulation Blockers
- Dphc 317 Bronchodilators
- Dphc 318 Methylxanthines
- Dphc 319 Methylxanthine: Adverse Effects
- Dphc 320 β -Adrenergic Agonists

Cough

- Dphc 329 Cough
- Dphc 330 Cough Suppressants (Antitussive Agents)

Chronic Obstructive Pulmonary Disease

- Dphc 331 Chronic Obstructive Pulmonary Disease
- Dphc 332 Emphysema
- Dphc 333 Emphysema Causes
- Dphc 334 Inherited Emphysema
- Dphc 335 Chronic Bronchitis
- Dphc 336 COPD: General Treatment Measures
- Dphc 337 COPD: Specific Drug Treatments

Restrictive Pulmonary Disease

- Dphc 338 Restrictive Pulmonary Disease
- Dphc 339 Pneumonia
- Dphc 341 Viral Pneumonia
- Dphc 343 Bacterial Pneumonia

Drugs used in Disorders of the Reproductive System

Organization and Function of the Reproductive System

- Dphc 346 Organization of the Reproductive System
- Dphc 347 Regulation of Estrogen and Testosterone
- Dphc 348 Event of the Normal Menstrual Cycle

Contraception

- Dphc 349 Combination Oral Contraceptives
- Dphc 350 Major Adverse Effects of Combination Oral Contraceptives
- Dphc 351 Estrogen and Coagulation
- Dphc 352 Progestin-Only Contraceptives
- Dphc 353 The Morning-After Pill
- Dphc 354 The Abortion Pill

Endometriosis and Treatment

- Dphc 355 Endometriosis
- Dphc 356 Danazol
- Dphc 357 Gonadotropin-Releasing Hormone Agonists, Combination oral Contraceptives, and Progestin

Postmenopausal Hormone Changes and Therapy

- Dphc 358 Estrogen Decline
- Dphc 359 Vasomotor Symptoms
- Dphc 360 Genitourinary Atrophy
- Dphc 361 Osteoporosis and Estrogen
- Dphc 362 Role of Progestins in Hormone Replacement Therapy
- Dphc 363 Route of Hormone Administration
- Dphc 364 General Adverse Effects
- Dphc 365 Cardiovascular and Neurologic Risks
- Dphc 366 Cancer Risks

Selective Estrogen Receptor Modulators and Antiestrogens

- Dphc 367 Selective Estrogen Receptor Modulators
- Dphc 368 Antiestrogens


Hypogonadism

- Dphc 369 Hypogonadism
- Dphc 370 Hypogonadism Treatment and Effects

Drugs used to Affects Renal Function

Organization and Functions of the Renal System

- Dphc 372 Macroscopic Anatomy
- Dphc 373 The Nephron
- Dphc 374 Blood Vessels Surrounding Nephrons
- Dphc 375 The Glomerulus
- Dphc 376 Practical Application: Measuring the Glomerular Filtration Rate
- Dphc 377 Tubular Segments
- Dphc 378 Ion and Water Reabsorption
- Dphc 379 Bicarbonate Reabsorption
- Dphc 380 Potassium Excretion



Dphc 171



Size 20"x26"

Thick Laminated both side & attached with Plastic Strips

Thick Laminated & Framed on NU-Wood Board

Volume Regulation

- Dphc 381 Antidiuretic Hormone
- Dphc 382 Renin-Angiotensin-Aldosterone System

Diuretics

- Dphc 383 General Considerations: Volume Homeostasis
- Dphc 385 Mercurial Diuretics
- Dphc 386 Carbonic Anhydrase Inhibitors
- Dphc 387 Thiazide Diuretics
- Dphc 388 Potassium-Sparing Agents
- Dphc 389 Loop (High-Ceiling) Diuretics
- Dphc 390 Osmotic Agents
- Dphc 391 Summary of Therapeutics

Urinary Incontinence

- Dphc 393 Urinary Incontinence

Urinary Tract Calculi

- Dphc 394 Urinary Tract Calculi (Kidney Stones)

Renal Insufficiency and Dialysis

- Dphc 395 Effect of Renal Insufficiency on Drug Action
- Dphc 396 Effect of Hemodialysis on Drug Action

Drugs in Infectious Disease

Bacterial Infections: Antibiotics

- Dphc 398 Classification of Antibiotics
- Dphc 399 Definitions: Bacteriostatic Versus Bactericidal
- Dphc 400 Spectrum of Activity
- Dphc 401 Mechanisms of Resistance
- Dphc 402 Examples of Resistance
- Dphc 403 Natural Penicillins: Penicillin G and Penicillin V
- Dphc 404 Aminopenicillins; Amoxicillin and Ampicillin
- Dphc 405 Antipseudomonal Penicillins: Carbenicillin, Piperacillin, and Ticarcillin
- Dphc 406 b-Lactamase Inhibitors
- Dphc 407 b-Lactamase-Resistant Penicillins: Cloxacillin, Dicloxacillin, Oxacillin and Nafcillin
- Dphc 408 Adverse Effects of Penicillins
- Dphc 409 Cephalosporins
- Dphc 410 Carbapenems: Imipenem-Cilastatin, Ertapenem and Meropenem
- Dphc 411 Monobactams: Aztreonam
- Dphc 412 Vancomycin
- Dphc 413 Vancomycin Treatment Difficulties: Resistance and Adverse Effects
- Dphc 414 Tetracyclines
- Dphc 415 Aminoglycosides
- Dphc 416 Macrolides: Erythromycin, Azithromycin, and Clarithromycin
- Dphc 417 Clindamycin
- Dphc 418 Quinolones
- Dphc 419 New-Generation Quinolones
- Dphc 421 Quinupristin/Dalfopristin
- Dphc 422 Linezolid
- Dphc 423 Sulfonamides

Fungal Infections: Antifungal Drugs

- Dphc 424 Nature of Fungal Infections and Therapy
- Dphc 425 Amphotericin B
- Dphc 426 Azole Antifungal Agents and Other Antifungal Agents

Viral Infections and Antiviral Agents

- Dphc 427 Nature of Viral Infections
- Dphc 428 Herpesviruses
- Dphc 429 Acyclovir and Famciclovir
- Dphc 430 Ganciclovir
- Dphc 431 Influenza and Its Treatment

HIV Infection: Antiretroviral Agents

- Dphc 432 HIV Infection
- Dphc 433 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-NRTIs
- Dphc 434 Protease Inhibitors
- Dphc 435 Other Antiretroviral Agents for AIDS: Tenofovir and Enfuvirtide

Drugs used in Neoplastic Disorders

Introduction to chemotherapy

- Dphc 438 Cell Cycle
- Dphc 439 Combination Chemotherapy
- Dphc 440 Adverse Effects of Chemotherapy

Antimetabolites

- Dphc 441 Folate Analogs: Methotrexate
- Dphc 442 Purine Analogs: Mercaptopurine and Thioguanine
- Dphc 443 Pyrimidine Analogs : 5-Fluorouracil
- Dphc 444 Pyrimidine Analogs: Capecitabine
- Dphc 445 Pyrimidine Analogs: Cytarabine and Fludarabine
- Dphc 446 Pyrimidine Analogs: Gemcitabine
- Dphc 447 Substituted Ureas: Hydroxyurea

Alkylating Agents

- Dphc 448 Nitrogen Mustards: Mechlorethamine and Melphalan
- Dphc 449 Cyclophosphamide and Ifosfamide
- Dphc 450 Nitrosoureas: Carmustine and Lomustine
- Dphc 451 Platinum Compounds: Cisplatin, Carboplatin and Oxaliplatin

Microtubule Inhibitors

- Dphc 452 Vinca Alkaloids: Vincristine, Vinblastine and Vinorelbine
- Dphc 453 Taxanes

Antibiotics

- Dphc 454 Anthracyclines: Doxorubicin and Daunorubicin

Hormonal Therapies

- Dphc 455 Estrogen Antagonists: Tamoxifen and Toremifene
- Dphc 456 Aromatase Inhibitors: Anastrozole Letrozole and Exemestane
- Dphc 457 Gonadotropin-Releasing Hormone Analogs: Leuprolide and Goserelin
- Dphc 458 Antiandrogens: Flutamide, Bicalutamide and Nilutamide

Monoclonal Antibodies

- Dphc 459 Unconjugated Antibodies: Trastuzumab, Alemtuzumab and Rituximab
- Dphc 460 Conjugated Antibodies: Ibritumomab Tiuxetan and Tositumomab and Iodine I 131 Tositumomab

Newer Miscellaneous Agents

- Dphc 461 Imatinib Mesylate
- Dphc 462 Gefinitib
- Dphc 463 Bortezomib

Drugs used for skin Disorders

- Dphc 466 Anatomy of the Skin

Hair Loss

- Dphc 467 Alopecia

Blister Diseases

- Dphc 468 Bullous (Blister) Skin Diseases

Eczema

- Dphc 469 Common Dermatoses Including Eczema

Size 20"x26"

**Thick Laminated both side & attached with Plastic Strips
Thick Laminated & Framed on NU-Wood Board**

Psoriasis

Dphc 470 Psoriasis

Mite and Louse Infestations

Dphc 471 Scabies and Pediculosis

Hives

Dphc 472 Urticaria

Vitamins: Deficiencies and Drug Interactions

Fat-Soluble Vitamins

Dphc 474 Deficiency of Vitamin A (Retinol) and Other Fat-Soluble Vitamins

Water-Soluble Vitamins

Dphc 475 Deficiency of Thiamine (B1) and Other B Vitamins
Dphc 476 Niacin or Nicotine Acid Deficiency (Pellagra)
Dphc 477 Vitamin C Deficiency (Scurvy)

Vitamin-Drug Interactions

Dphc 478 Fat-Soluble Vitamin-Drug Interactions
Dphc 479 Water-Soluble Vitamin-Drug Interactions

Drug Allergy, Abuse, and Poisoning or Overdose

Drug Allergy


Dphc 482 Allergic Reactions to Drugs
Dphc 483 Type I (Acute, Anaphylactic) Reactions
Dphc 484 Type II (Cytotoxic, Autoimmune) Reactions
Dphc 485 Type III (Immune Complex, Serum Sickness, Arthus) Reactions
Dphc 486 Type IV (Cell-Mediated, Delayed-Hypersensitivity, Contact Dermatitis) Reactions

Drug Abuse

Dphc 487 Brain Reward Circuit
Dphc 488 Ethanol: Deleterious Effects
Dphc 489 Ethanol Abuse: Treatment
Dphc 490 Withdrawal: Opioids, Benzobiazepines and Barbiturates

Poisoning or Overdose

Dphc 492 Sympathomimetic Drugs
Dphc 493 Cholinergic Drugs
Dphc 494 Anticholinergic Drugs
Dphc 495 Serotonergics
Dphc 496 Opioids
Dphc 497 Over-the-Counter Products
Dphc 498 Management of Poisoning and Overdose



Dphc 403

History of Medicine

Size 20"x26"

**Thick Laminated both side & attached with Plastic Strips
Thick Laminated & Framed on NU-Wood Board**

Set of 10 Charts



History of Medicine -I

History of Medicine -II

History of Medicine -III

- History of Medicine -I
- History of Medicine -II
- History of Medicine -III
- History of Medicine -IV
- History of Medicine -V
- History of Medicine -VI
- History of Medicine -VII
- History of Medicine -VIII
- History of Medicine -IX
- History of Medicine -X



MEDICINAL HERBS PHOTOGRAPHS

Pharmacology (Dbios)

Size 12"X18" Approx

CH 2600 PHARMACIST'S OATH

CH 2601 BAHERA
CH 2602 ARCHI OIL
CH 2603 PAPAIN
CH 2604 SHANKHPUSHPI
CH 2605 SHARK LIVER OIL
CH 2606 COTTON
CH 2607 ASWAGANDHA
CH 2608 TAMARINDS
CH 2609 SENNA LEAVES
CH 2610 BRAHMI
CH 2611 PUNARNAVA
CH 2612 RHUBARB
CH 2613 NEEM OIL
CH 2614 AJOWAN
CH 2615 STROPHANTHUS
CH 2616 BAEL
CH 2617 ACACIA (INDIAN GUM)
CH 2618 COCOA
CH 2619 TURMERIC
CH 2620 BITTER ORANGE PEEL
CH 2621 NUX-VOMICA
CH 2622 BLACK PEPPER
CH 2623 OPIUM
CH 2624 JATAMANSI
CH 2625 CANNABIS

CH 2626 VINCA
CH 2627 ISAPGOL (ISPAGHULA)
CH 2628 GINGER
CH 2629 CINNAMON
CH 2630 VASAKA
CH 2631 CELERY
CH 2632 ARJUNA BARK
CH 2633 VALERIAN
CH 2634 CLOVE BUD
CH 2635 LINSEED OIL
CH 2636 GYMNEMA
CH 2637 NUTMEG
CH 2638 DIGITALIS
CH 2639 CHAULMOOGRA
CH 2640 GINSENG ROOTS
CH 2641 EUCALYPTUS
CH 2642 BLACK CATECHU
CH 2643 GARLIC
CH 2644 PEPPERMINT
CH 2645 TULSI
CH 2646 PYRETHRUM
CH 2647 AMLA
CH 2648 MOMORDICA
CH 2649 CUMMIN
CH 2650 VIDANG
CH 2651 HYOSCYAMUS

CH 2652 SAGE
CH 2653 DIOSCOREA
CH 2654 L.H.ERGOT
CH 2655 ALOE
CH 2656 ALMONDS
CH 2657 LEMON PEELS
CH 2658 THEVETIA
CH 2659 PICRORRHIZA
CH 2660 YEAST

Ask for complete List



CH 2655

PHARMACOLOGY INSTRUMENT

A Few basic instrument for the Pharmacology Lab

S No.	Instrument Name
1.	LEGANDROFF/ PERFUSION ASSEMBLY
2.	ELECTRIC KYMOGRAPH MODEL E-8
3.	MECHANICAL STIRRER
4.	VARNISHING TRAY WITH FOOT LEVER
5.	FOUR UNIT ORGAN BATH
6.	SINGLE UNIT ORGAN BATH
7.	ANALGENISMETER a.)Tail Flick Method b.)Eddy's Hot Plate Method
8.	FROG BOARD
9.	LONG EXTENSION FOR KYMOGRAPH
10.	METRANOME
11.	MERCURY MONOMETER
12.	POLE-CLIMBING APPARATUS
13.	ELECTRO-CONVULSIOMETER
14.	ACTIVITY CAGE/ACTOPHOTOMETER
15.	HISTAMINE CHAMBER
16.	PLETHYSMOGRAPH
17.	TETNUS SET
18.	TELETHERMOMETER-6 PROBE
19.	PHYSIOGRAPH-SINGLE CHANNEL
20.	PHYSIOGRAPH- THREE CHANNEL
21.	WATER DE-IONIZATION APPARATUS
22.	ROTAROD APPARATUS 2 COMP
23.	METABOLIC CAGES
24.	TABLET DISTEGRATION TEST APPARATUS
25.	VORTEX SHAKER



CONVULSIOMETER



KYMOGRAPH

Size 20"x26"

Thick Laminated both side & attached with Plastic Strips
Thick Laminated & Framed on NU-Wood Board

Dbios FAMOUS PHARMACOLOGY PIONEERS

1. Rudolf Buchheim Father of Pharmacology
2. Paul Greengard 2000
3. Robert F. Furchgott 1998
4. Louis J. Ignarro 1998
5. Ferid Murad 1998
6. Alfred G. Gilman 1994
7. Edwin G. Krebs 1992
8. Sir James W. Black 1998
9. Gertrude B. Elion 1988
10. Earl W. Sutherland JR. 1971
11. Julius Axelrod 1970
12. Linus Carl Pauling 1954
13. Herbert Spencer Gasser 1944
14. Corneille J.F. Heymans 1938
15. Otto Loewi 1936
16. Sir Henry Hallett Dale 1936
17. Frederick Grant Banting 1923
18. **Oswald Schmiedeberg** (1838-1921)
19. Dr. Naranjan Dhalla
20. Gerhard Johannes Paul Domagk (Nobilest)
Col. Ramnath Chopra Father of Indian Pharmacology
21. Albert niemann
22. ARWID CARLSSON
23. Crawford Long
24. Friedrich Wilhelm Sertner
25. George Hitchings (Nobilest)
26. James Parkinson
27. John-Gaddum
28. Howard Walter Florey
29. Sir John Vane
30. Karl Koller
31. Ludwig Laqueur
32. Sir James Whyte Black
33. Wzilliam T. G. Morton
34. William Withering



Sir Howard Walter FLOREY



CRUDE DRUGS

Powdered Drugs, Natural Colours, Oils, Fibers etc. To be supplied in pearlpet jars.

With detail descriptions on separate framed key cards (Set of 100)